Clinical Professor Alan Coates AM

Clinical Professor
Public Health, School of Public Health
NHMRC Clinical Trials Centre

K25 - Medical Foundation Building
The University of Sydney
NSW 2006 Australia

T: +61 2 9331 3521
F: none
E:

W: Related website

Biographical details

Alan Coates graduated in Medicine from the University of Melbourne in 1966, and trained at the Royal Melbourne Hospital and the Walter and Eliza Hall Institute for Medical Research in Australia, then at the Wisconsin Clinical Cancer Center in the United States. After returning to Australia in 1978 he practised as a medical oncologist in Sydney. He was appointed Associate Professor in Cancer Medicine in the University of Sydney in 1985. Since 1998 he has been a Clinical Professor in the School of Public Health in the University of Sydney. [More...]

Research interests

Professor Coates is involved in international breast cancer clinical trials research, and studies of the value of tumor markers in the prediction of therapeutic effectiveness.

Collaborations include the Garvan Institute, Sydney, the European Institute of Oncology, Milan, and the Dana Farber Cancer Center, Boston

International links

Italy. (European Institute of Pathology) Co-author and statistician.
United Kingdom. (Oxford University Clinical Trials Service Unit) Member, Steering Committee, Early Breast Cancer Trialists Collaborative Group.
Italy. (University of Turin, Department of Pathology (Prof Anna Sapino)) Co-author and statistician.
United Kingdom. (Imperial College and Charing Cross Hospital, London) Member, Steering Committee, International Exemestane Study.
United States. (Dana-Farber Cancer Institute, Harvard Medical School) Visiting scientist.
Switzerland. (International Breast Cancer Study Group) Co-Chair of Scientific Committee and Member of Foundation Council.

Publications

2013 | 2012 | 2011 | 2010 | 2009 | 2008

2013

   
  • Regan, M., Pagani, O., Fleming, G., Walley, B., Price, K., Rabaglio, M., Maibach, R., Ruepp, B., Coates, A., Goldhirsch, A., Colleoni, M., Gelber, R., Francis, P. (2013), Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials. Breast. 22(6), 1094-1100. [Abstract]
  • Goldhirsch, A., Winer, E., Coates, A., Gelber, R., Piccart-Gebhart, M., Thurlimann, B., Senn, H. (2013), Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Annals of Oncology. 24(9), 2206-2223. [Abstract]
  • Metzger-Filho, O., Sun, Z., Viale, G., Price, K., Crivellari, D., Snyder, R., Gelber, R., Castiglione-Gertsch, M., Coates, A., Goldhirsch, A., Cardoso, F. (2013), Patterns of Recurrence and Outcome According to Breast Cancer Subtypes in Lymph Node-Negative Disease: Results From International Breast Cancer Study Group Trials VIII and IX. Journal of Clinical Oncology. 31(25), 3083-3091. [Abstract]
  • Crivellari, D., Gray, K., Dellapasqua, S., Puglisi, F., Ribi, K., Price, K., Lang, I., Gianni, L., Spazzapan, S., Pinotti, G., Luthi, J., Gelber, R., Regan, M., Colleoni, M., Castiglione-Gertsch, M., Maibach, R., Rabaglio, M., Coates, A., Goldhirsch, A. (2013), Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a "standard chemotherapy regimen": the CASA randomized trial. Breast (Edinburgh, Scotland). 22(2), 130-137. [Abstract]
  • Galimberti, V., Cole, B., Zurrida, S., Viale, G., Luini, A., Veronesi, P., Baratella, P., Chifu, C., Sargenti, M., Intra, M., Gentilini, O., Mastropasqua, M., Mazzarol, G., Massarut, S., Garbay, J., Zgajnar, J., Galatius, H., Recalcati, A., Littlejohn, D., Bamert, M., Colleoni, M., Price, K., Regan, M., Goldhirsch, A., Coates, A., Gelber, R., Veronesi, U. (2013), Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. The Lancet Oncology. 14(4), 297-305. [Abstract]
  • Lee, C., Gebski, V., Coates, A., Veillard, A., Harvey, V., Tattersall, M., Byrne, M., Brigham, B., Forbes, J., Simes, R. (2013), Trade-offs in quality of life and survival with chemotherapy for advanced breast cancer: mature results of a randomized trial comparing single-agent mitoxantrone with combination cyclophosphamide, methotrexate, 5-fluorouracil and prednisone. SpringerPlus. 2, 391. [Abstract]

2012

   
  • Coates, A., Millar, E., O'Toole, S., Molloy, T., Viale, G., Goldhirsch, A., Regan, M., Gelber, R., Sun, Z., Castiglione-Gertsch, M., Gusterson, B., Musgrove, E., Sutherland, R. (2012), Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX. Breast Cancer Research. 14(6), R143. [Abstract]
  • Huober, J., Gelber, S., Goldhirsch, A., Coates, A., Viale, G., ÿhlschlegel, C., Price, K., Gelber, R., Regan, M., Thürlimann, B. (2012), Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials. Annals of Oncology. 23(11), 2843-2851. [Abstract]
  • Ewertz, M., Gray, K., Regan, M., Ejlertsen, B., Price, K., Thürlimann, B., Bonnefoi, H., Forbes, J., Paridaens, R., Rabaglio, M., Gelber, R., Colleoni, M., Láng, I., Smith, I., Coates, A., Goldhirsch, A., Mouridsen, H. (2012), Obesity and Risk of Recurrence or Death After Adjuvant Endocrine Therapy With Letrozole or Tamoxifen in the Breast International Group 1-98 Trial. Journal of Clinical Oncology. 30(32), 3967-3975. [Abstract]
  • Ribi, K., Aldridge, J., Phillips, K., Thompson, A., Harvey, V., Thürlimann, B., Cardoso, F., Pagani, O., Coates, A., Goldhirsch, A., Price, K., Gelber, R., Bernhard, J. (2012), Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer. British Journal of Cancer. 106(10), 1618-1625. [Abstract]
  • Coates, A., Colleoni, M., Goldhirsch, A. (2012), Is adjuvant chemotherapy useful for women with luminal a breast cancer?. Journal of Clinical Oncology. 30(12), 1260-1263. [Abstract]
  • Regan, M., Leyland-Jones, B., Bouzyk, M., Pagani, O., Tang, W., Kammler, R., Dell'orto, P., Biasi, M., Thürlimann, B., Lyng, M., Ditzel, H., Neven, P., Debled, M., Maibach, R., Price, K., Gelber, R., Coates, A., Goldhirsch, A., Rae, J., Viale, G. (2012), CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. Journal of the National Cancer Institute. 104(6), 441-451. [Abstract]
  • Bliss, J., Kilburn, L., Coleman, R., Forbes, J., Coates, A., Jones, S., Jassem, J., Delozier, T., Andersen, J., Paridaens, R., van de Velde, C., Lonning, P., Morden, J., Reise, J., Cisar, L., Menschik, T., Coombes, R. (2012), Disease-Related Outcomes With Long-Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study. Journal of Clinical Oncology. 30(7), 709-717. [Abstract]
  • Chirgwin, J., Sun, Z., Smith, I., Price, K., Thürlimann, B., Ejlertsen, B., Bonnefoi, H., Regan, M., Goldhirsch, A., Coates, A. (2012), The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause. Breast cancer research and treatment. 131(1), 295-306. [Abstract]

2011

   
  • Stockler, M., Harvey, V., Francis, P., Byrne, M., Ackland, S., Fitzharris, B., Van Hazel, G., Wilcken, N., Grimison, P., Nowak, A., Gainford, M., Fong, A., Paksec, L., Sourjina, T., Zannino, D., Gebski, V., Simes, R., Forbes, J., Coates, A. (2011), Capecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil As First-Line Chemotherapy for Advanced Breast Cancer. Journal of Clinical Oncology. 29(34), 4498-4504. [Abstract]
  • Regan, M., Neven, P., Giobbie-Hurder, A., Goldhirsch, A., Ejlertsen, B., Mauriac, L., Forbes, J., Smith, I., Láng, I., Wardley, A., Rabaglio, M., Price, K., Gelber, R., Coates, A., Thürlimann, B. (2011), Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. The lancet oncology. 12(12), 1101-8. [Abstract]
  • Karlsson, P., Sun, Z., Braun, D., Price, K., Castiglione-Gertsch, M., Rabaglio, M., Gelber, R., Crivellari, D., Collins, J., Murray, E., Zaman, K., Colleoni, M., Gusterson, B., Viale, G., Regan, M., Coates, A., Goldhirsch, A. (2011), Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 22(10), 2216-26. [Abstract]
  • Viale, G., Regan, M., Dell'orto, P., Mastropasqua, M., Maiorano, E., Rasmussen, B., Macgrogan, G., Forbes, J., Paridaens, R., Colleoni, M., Láng, I., Thürlimann, B., Mouridsen, H., Mauriac, L., Gelber, R., Price, K., Goldhirsch, A., Gusterson, B., Coates, A. (2011), Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 22(10), 2201-7. [Abstract]
  • Aebi, S., Sun, Z., Braun, D., Price, K., Castiglione-Gertsch, M., Rabaglio, M., Gelber, R., Crivellari, D., Lindtner, J., Snyder, R., Karlsson, P., Simoncini, E., Gusterson, B., Viale, G., Regan, M., Coates, A., Goldhirsch, A. (2011), Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: Long-term follow up on IBCSG Trial IX. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 22(9), 1981-7. [Abstract]
  • Lee, C., Hudson, M., Stockler, M., Coates, A., Ackland, S., Gebski, V., Lord, S., Friedlander, M., Boyle, F., Simes, R. (2011), A nomogram to predict survival time in women starting first-line chemotherapy for advanced breast cancer. Breast cancer research and treatment. 129(2), 467-76. [Abstract]
  • Goldhirsch, A., Wood, W., Coates, A., Gelber, R., Thürlimann, B., Senn, H. (2011), Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Annals of Oncology. 22(8), 1736-1747. [Abstract]
  • Colleoni, M., Giobbie-Hurder, A., Regan, M., Thürlimann, B., Mouridsen, H., Mauriac, L., Forbes, J., Paridaens, R., Láng, I., Smith, I., Chirgwin, J., Pienkowski, T., Wardley, A., Price, K., Gelber, R., Coates, A., Goldhirsch, A. (2011), Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. Journal of Clinical Oncology. 29(9), 1117-1124. [Abstract]
  • Phillips, K., Aldridge, J., Ribi, K., Sun, Z., Thompson, A., Harvey, V., Thürlimann, B., Cardoso, F., Pagani, O., Coates, A., Goldhirsch, A., Price, K., Gelber, R., Bernhard, J. (2011), Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial. Breast Cancer Research and Treatment. 126(1), 221-226. [Abstract]

2010

   
  • Castellano, I., Allia, E., Accortanzo, V., Vandone, A., Chiusa, L., Arisio, R., Durando, A., Donadio, M., Bussolati, G., Coates, A., Viale, G., Sapino, A. (2010), Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers. Breast cancer research and treatment. 124, 607-17. [Abstract]
  • Phillips, K., Ribi, K., Sun, Z., Stephens, A., Thompson, A., Harvey, V., Thürlimann, B., Cardoso, F., Pagani, O., Coates, A., Goldhirsch, A., Price, K., Gelber, R., Bernhard, J. (2010), Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial. Breast (Edinburgh, Scotland). 19(5), 388-95. [Abstract]
  • Paridaens, R., Gelber, S., Cole, B., Gelber, R., Thürlimann, B., Price, K., Holmberg, S., Crivellari, D., Coates, A., Goldhirsch, A. (2010), Adjuvant! Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer. Breast Cancer Research and Treatment. 123(1), 303-310. [Abstract]
  • Colleoni, M., Cole, B., Viale, G., Regan, M., Price, K., Maiorano, E., Mastropasqua, M., Crivellari, D., Gelber, R., Goldhirsch, A., Coates, A., Gusterson, B. (2010), Classical Cyclophosphamide, Methotrexate, and Fluorouracil Chemotherapy Is More Effective in Triple-Negative, Node-Negative Breast Cancer: Results From Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(18), 2966-73. [Abstract]
  • Maiorano, E., Regan, M., Viale, G., Mastropasqua, M., Colleoni, M., Castiglione-Gertsch, M., Price, K., Gelber, R., Goldhirsch, A., Coates, A. (2010), Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer: Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy. Breast cancer research and treatment. 121(1), 211-8. [Abstract]
  • Lee, C., Stockler, M., Coates, A., Gebski, V., Lord, S., Simes, R. (2010), Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer. British journal of cancer. 102(9), 1341-7. [Abstract]
  • Viale, G., Giobbie-Hurder, A., Gusterson, B., Maiorano, E., Mastropasqua, M., Sonzogni, A., Mallon, E., Colleoni, M., Castiglione-Gertsch, M., Regan, M., Price, K., Brown, R., Golouh, R., Crivellari, D., Karlsson, P., Ohlschlegel, C., Gelber, R., Goldhirsch, A., Coates, A. (2010), Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 21(2), 245-54. [Abstract]
  • Lee, C., Lord, S., Stockler, M., Coates, A., Gebski, V., Simes, R. (2010), Historical cross-trial comparisons for competing treatments in advanced breast cancer - An empirical analysis of bias. European journal of cancer (Oxford, England : 1990). 46(3), 541-8. [Abstract]

2009

   
  • Pagani, O., Price, K., Gelber, R., Castiglione-Gertsch, M., Holmberg, S., Lindtner, J., Thürlimann, B., Collins, J., Fey, M., Coates, A., Goldhirsch, A. (2009), Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century. Breast Cancer Research and Treatment. 117(2), 319-324. [Abstract]
  • Viale, G., Rotmensz, N., Maisonneuve, P., Orvieto, E., Maiorano, E., Galimberti, V., Luini, A., Colleoni, M., Goldhirsch, A., Coates, A. (2009), Lack of prognostic significance of "classic" lobular breast carcinoma: a matched, single institution series. Breast cancer research and treatment. 117(0), 211-4. [Abstract]
  • Rabaglio, M., Sun, Z., Price, K., Castiglione-Gertsch, M., Hawle, H., Thürlimann, B., Mouridsen, H., Campone, M., Forbes, J., Paridaens, R., Colleoni, M., Pienkowski, T., Nogaret, J., Láng, I., Smith, I., Gelber, R., Goldhirsch, A., Coates, A. (2009), Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Annals of oncology. 20(9), 1489-1498. [Abstract]
  • Mouridsen, H., Giobbie-Hurder, A., Goldhirsch, A., Thürlimann, B., Paridaens, R., Smith, I., Mauriac, L., Forbes, J., Price, K., Regan, M., Gelber, R., Coates, A. (2009), Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. New England Journal of Medicine. 361(8), 766-776. [Abstract]
  • Pagani, O., Gelber, S., Simoncini, E., Castiglione-Gertsch, M., Price, K., Gelber, R., Holmberg, S., Crivellari, D., Collins, J., Lindtner, J., Thürlimann, B., Fey, M., Murray, E., Forbes, J., Coates, A., Goldhirsch, A. (2009), Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93. Breast Cancer Research and Treatment. 116(3), 491-500. [Abstract]
  • Colleoni, M., Sun, Z., Martinelli, G., Basser, R., Coates, A., Gelber, R., Green, M., Peccatori, F., Cinieri, S., Aebi, S., Viale, G., Price, K., Goldhirsch, A. (2009), The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up. Annals of Oncology. 20(8), 1344-1351. [Abstract]
  • Goldhirsch, A., Ingle, J., Gelber, R., Coates, A., Thürlimann, B., Senn, H. (2009), Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Annals of Oncology. 20(8), 1319-1329. [Abstract]
  • Lee, C., Lord, S., Coates, A., Simes, R. (2009), Molecular biomarkers to individualise treatment: assessing the evidence. The Medical Journal of Australia. 190(11), 631-636. [Abstract]
  • Gianni, L., Gelber, S., Ravaioli, A., Price, K., Panzini, I., Fantini, M., Castiglione-Gertsch, M., Pagani, O., Simoncini, E., Gelber, R., Coates, A., Goldhirsch, A. (2009), Second non-breast primary cancer following adjuvant therapy for early breast cancer: a report from the International Breast Cancer Study Group. European Journal of Cancer. 45(4), 561-571. [Abstract]
  • Thürlimann, B., Price, K., Gelber, R., Holmberg, S., Crivellari, D., Colleoni, M., Collins, J., Forbes, J., Castiglione-Gertsch, M., Coates, A., Goldhirsch, A. (2009), Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93. Breast cancer research and treatment. 113(1), 137-44. [Abstract]

2008

   
  • Viale, G., Giobbie-Hurder, A., Regan, M., Coates, A., Mastropasqua, M., Dell'orto, P., Maiorano, E., Macgrogan, G., Braye, S., Ohlschlegel, C., Neven, P., Orosz, Z., Olszewski, W., Knox, F., Thürlimann, B., Price, K., Castiglione-Gertsch, M., Gelber, R., Gusterson, B., Goldhirsch, A. (2008), Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(34), 5569-75. [Abstract]
  • Juraskova, I., Butow, P., Lopez, A., Seccombe, M., Coates, A., Boyle, F., McCarthy, N., Reaby, L., Forbes, J. (2008), Improving informed consent: pilot of a decision aid for women invited to participate in a breast cancer prevention trial (IBIS-II DCIS). Health Expectations. 11(3), 252-262. [Abstract]
  • Gruber, G., Cole, B., Castiglione-Gertsch, M., Holmberg, S., Lindtner, J., Golouh, R., Collins, J., Crivellari, D., Thürlimann, B., Simoncini, E., Fey, M., Gelber, R., Coates, A., Price, K., Goldhirsch, A., Viale, G., Gusterson, B. (2008), Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer. Annals of Oncology. 19(8), 1393-1401. [Abstract]
  • Duric, V., Butow, P., Sharpe, L., Heritier, S., Boyle, F., Beith, J., Wilcken, N., Coates, A., Simes, R., Stockler, M. (2008), Comparing patients' and their partners' preferences for adjuvant chemotherapy in early breast cancer. Patient Education and Counseling. 72(2), 239-245. [Abstract]
  • Regan, M., Pagani, O., Walley, B., Torrisi, R., Perez, E., Francis, P., Fleming, G., Price, K., Thürlimann, B., Maibach, R., Castiglione-Gertsch, M., Coates, A., Goldhirsch, A., Gelber, R. (2008), Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?. Annals of Oncology. 19(7), 1231-1241. [Abstract]
  • Pestalozzi, B., Zahrieh, D., Mallon, E., Gusterson, B., Price, K., Gelber, R., Holmberg, S., Lindtner, J., Snyder, R., Thürlimann, B., Murray, E., Viale, G., Castiglione-Gertsch, M., Coates, A., Goldhirsch, A. (2008), Distinct Clinical and Prognostic Features of Infiltrating Lobular Carcinoma of the Breast: Combined Results of 15 International Breast Cancer Study Group Clinical Trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(18), 3006-14. [Abstract]
  • Wapnir, I., Aebi, S., Geyer, C., Zahrieh, D., Gelber, R., Anderson, S., Robidoux, A., Bernhard, J., Maibach, R., Castiglione-Gertsch, M., Coates, A., Piccart, M., Clemons, M., Costantino, J., Wolmark, N. (2008), A randomized clinical trial of adjuvant chemotherapy for radically resected locoregional relapse of breast cancer: IBCSG 27-02, BIG 1-02, and NSABP B-37. Clinical Breast Cancer. 8(3), 287-292. [Abstract]
  • Untch, M., Gelber, R., Jackisch, C., Procter, M., Baselga, J., Bell, R., Cameron, D., Bari, M., Smith, I., Leyland-Jones, B., de Azambuja, E., Wermuth, P., Khasanov, R., Feng-Yi, F., Constantin, C., Mayordomo, J., Su, C., Yu, S., Lluch, A., Senkus-Konefka, E., Price, C., Haslbauer, F., Sahui, T., Srimuninnimit, V., Colleoni, M., Coates, A., Piccart-Gebhart, M., Goldhirsch, A. (2008), Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 19(6), 1090-6. [Abstract]
  • Crivellari, D., Sun, Z., Coates, A., Price, K., Thürlimann, B., Mouridsen, H., Mauriac, L., Forbes, J., Paridaens, R., Castiglione-Gertsch, M., Gelber, R., Colleoni, M., Láng, I., Del Mastro, L., Gladieff, L., Rabaglio, M., Smith, I., Chirgwin, J., Goldhirsch, A. (2008), Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. Journal of Clinical Oncology. 26(12), 1972-1979. [Abstract]
  • Ravaioli, A., Monti, F., Regan, M., Maffini, F., Mastropasqua, M., Spataro, V., Castiglione-Gertsch, M., Panzini, I., Gianni, L., Goldhirsch, A., Coates, A., Price, K., Gusterson, B., Viale, G. (2008), p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer. Annals of oncology. 19(4), 660-668. [Abstract]
  • Viale, G., Regan, M., Maiorano, E., Mastropasqua, M., Golouh, R., Perin, T., Brown, R., Kovács, A., Pillay, K., Ohlschlegel, C., Braye, S., Grigolato, P., Rusca, T., Gelber, R., Castiglione-Gertsch, M., Price, K., Goldhirsch, A., Gusterson, B., Coates, A. (2008), Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group. Journal of Clinical Oncology. 26(9), 1404-1410. [Abstract]
  • Viale, G., Regan, M., Mastropasqua, M., Maffini, F., Maiorano, E., Colleoni, M., Price, K., Golouh, R., Perin, T., Brown, R., Kovács, A., Pillay, K., Ohlschlegel, C., Gusterson, B., Castiglione-Gertsch, M., Gelber, R., Goldhirsch, A., Coates, A. (2008), Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. Journal of the National Cancer Institute. 100(3), 207-212. [Abstract]
  • Bernhard, J., Zahrieh, D., Zhang, J., Martinelli, G., Basser, R., Hürny, C., Forbes, J., Aebi, S., Yeo, W., Thürlimann, B., Green, M., Colleoni, M., Gelber, R., Castiglione-Gertsch, M., Price, K., Goldhirsch, A., Coates, A. (2008), Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer. British journal of cancer. 98(1), 25-33. [Abstract]
  • Early Breast Cancer Trialists' Collaborative Group, Z., Clarke, M., Coates, A., Darby, S., Davies, C., Gelber, R., Godwin, J., Goldhirsch, A., Gray, R., Peto, R., Pritchard, K., Wood, W. (2008), Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet. 371(9606), 29-40. [Abstract]
  • Rasmussen, B., Regan, M., Lykkesfeldt, A., Dell'Orto, P., Del Curto, B., Henriksen, K., Mastropasqua, M., Price, K., Méry, E., Lacroix-Triki, M., Braye, S., Altermatt, H., Gelber, R., Castiglione-Gertsch, M., Goldhirsch, A., Gusterson, B., Thürlimann, B., Coates, A., Viale, G. (2008), Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. The Lancet oncology. 9(1), 23-28. [Abstract]
  • Gianni, L., Cole, B., Panzini, I., Snyder, R., Holmberg, S., Byrne, M., Crivellari, D., Colleoni, M., Aebi, S., Simoncini, E., Pagani, O., Castiglione-Gertsch, M., Price, K., Goldhirsch, A., Coates, A., Ravaioli, A. (2008), Anemia during adjuvant non-taxane chemotherapy for early breast cancer: Incidence and risk factors from two trials of the International Breast Cancer Study Group. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 16(1), 67-74. [Abstract]